Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Background: We retrospectively analysed relapsed/refractory MM (RRMM) patients treated with pomalidomide and dexamethasone (PomaD) either in real life, or previously enrolled in an interventional (STRATUS, MM-010) or currently enrolled in an observational study (MM-015) to provide further insights o...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Marina Silvia, Leotta, Salvatore, Romano, Alessandra, Del Fabro, Vittorio, Martino, Enrica Antonia, Calafiore, Valeria, Giubbolini, Rachele, Markovic, Uros, Leotta, Valerio, Di Giorgio, Mary Ann, Tibullo, Daniele, Di Raimondo, Francesco, Conticello, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832641/
https://www.ncbi.nlm.nih.gov/pubmed/31623097
http://dx.doi.org/10.3390/jcm8101695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832641/
https://www.ncbi.nlm.nih.gov/pubmed/31623097
http://dx.doi.org/10.3390/jcm8101695

Ejemplares similares